3 Growth Stocks With Real Earnings Upside and Stronger Balance Sheets

With markets focused on energy costs, inflation risks and shifting central bank policies, many investors are looking for companies where analysts still see clear room for earnings growth and balance sheets that can handle tougher conditions. The Healthy high growth potential screener is designed to highlight exactly that type of opportunity by filtering for stocks where analysts expect strong earnings growth over the next 3 years and an acceptable financial position. In this article, you will see 3 of the best stocks from this screener, giving you a focused starting list to research for your own portfolio.

Overview: MaxLinear is a semiconductor company that designs communications system-on-chip solutions used in high-speed data center optics, 4G/5G base stations, broadband gateways, Wi-Fi routers, and other networking hardware for telecom, cloud, and enterprise customers worldwide.

Operations: MaxLinear currently generates about US$568.9 million in revenue from its Semiconductors segment.

Market Cap: US$6.5b

MaxLinear is drawing attention because it sits at the intersection of AI data centers, 5G wireless and broadband upgrades. Recent Q2 2026 results show stronger demand from its optical AI data center products and a return to positive GAAP EPS. Forecasts for earnings and revenue growth, backed by partnerships with GCT Semiconductor, Edgecore Networks and Los Alamos National Laboratory, indicate meaningful exposure to long-term connectivity trends. At the same time, a high forecast return on equity highlights potential earnings power if expectations play out. On the other hand, the stock carries clear risks, including reliance on maturing broadband markets, intense pricing pressure in semiconductors, significant share price volatility and recent insider selling. These factors make the current high P/S multiple and analyst price targets important to scrutinize carefully.

MaxLinear’s AI data center story and forecast earnings potential look compelling, but the trade off between those expectations and today’s valuation is not straightforward. Reviewing the DCF valuation analysis for MaxLinear could surface one assumption that changes how you see the stock.

Overview: Liquidia is a biopharmaceutical company focused on treatments for rare cardiopulmonary diseases, led by its PRINT based inhaled treprostinil therapy YUTREPIA for pulmonary hypertension and a pipeline that includes the late stage candidate L606 and partnerships with larger industry players.

Operations: Liquidia generates about US$288.1 million in revenue from its Pharmaceuticals segment, all from the United States.

Market Cap: US$7.7b

Liquidia is attracting attention because early YUTREPIA uptake, improving payer access and rapid growth in reported revenue and profitability point to meaningful earnings power if prescription momentum and manufacturing expansion line up with expectations. The company is also building a second potential revenue stream through L606, which could share commercial and production infrastructure with YUTREPIA. At the same time, investors need to weigh high debt, heavy reliance on a single core product, ongoing patent litigation and recent insider selling against high earnings and revenue growth forecasts and index inclusion that has raised the stock’s profile. The combination of strong growth assumptions and concentrated risks makes Liquidia a high conviction, high scrutiny candidate within this screener.

Liquidia’s accelerating YUTREPIA story and late stage pipeline strengthen the growth case, but the real question is how that compares with concentrated product risk and litigation pressure in the analysis report for Liquidia

Overview: MP Materials is a rare earth producer that owns the Mountain Pass mine in California and manufactures high value NdFeB magnets and related materials used in electric vehicles, wind turbines and advanced electronics.

Operations: MP Materials currently generates about US$270.2 million from its Materials segment and US$82.7 million from Magnetics, with total reported revenue of roughly US$347.6 million, all from the United States.

Market Cap: US$7.4b

MP Materials gives you targeted exposure to rare earths and magnets that sit at the heart of EVs, clean energy and defense, underpinned by long term contracts with the U.S. government and large customers like Apple and GM that support revenue visibility. Analysts have published expectations for earnings and revenue growth and some see the stock trading below certain fair value estimates. The company is still loss making and heavily investing in capital intensive magnet plants, which brings execution, funding and customer concentration risks. With government equity support in place, a defined role in U.S. supply chain policy and a transition from raw materials to higher margin magnets, a central question for investors is whether current pricing reflects the full long term potential of MP Materials.

MP Materials’ shift from raw ore to higher value magnets could be masking the real story, and the 3 key rewards and 1 important warning sign reveals one underappreciated factor that could redefine how you size this opportunity

The three stocks in this article are just a starting point, and the full Healthy high growth potential screen on Simply Wall St has surfaced 1,517 more companies with equally compelling earnings and balance sheet stories in the Healthy high growth potential screener. Use Simply Wall St to identify, filter and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas faster.

Take Control of Your Investment Journey

If Liquidia or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly?

New ideas move fast, and the best setups often break out before most investors even notice. Scan fresh stock lists while the data still matters and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com